Introduction {#sec1}
============

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by insulin resistance (IR) in target tissues and a relative deficiency of insulin secretion from pancreatic β-cells \[[@cit0001]\]. Current evidence reveals an important role of inflammation and oxidative stress (OS) in T2DM development and progression. Furthermore, chronic hyperglycemia and IR promote a pro-oxidant environment and production of reactive oxygen species (ROS), while exhausting the endogenous antioxidative defense system \[[@cit0002], [@cit0003]\]. The consequent oxidative imbalance leads to further progression of the disease and development of micro- and macrovascular diabetic complications \[[@cit0004]\]. Therefore, strategies for preventing or reducing the inflammation and ROS imbalance could be a promising therapeutic tool in T2DM.

In recent decades, powerful evidence has shown that the physiological effects of vitamin D are not limited only to bone metabolism. It is believed that vitamin D has an extensive range of non-calcemic roles, and the antioxidative effect is newly suggested but rarely studied \[[@cit0002], [@cit0005]\]. Only a few controlled clinical trials have investigated the antioxidative effect of vitamin D supplementation in patients with T2DM, but a recent one confirmed that vitamin D can be used as a therapeutic agent along with other treatments for T2DM as it can improve glycated hemoglobin values (HbA~1c~) and IR. In the trials, different OS biomarkers were used, but most trials were focused on determining endogenous antioxidant status by assessing levels of defense enzymes (catalase, superoxide dismutase and glutathione peroxidase) and/or total antioxidant capacity. Some of the trials assessed OS by detecting products of oxidative damage, such as a lipid peroxidation marker (malondialdehyde), advanced glycation end products and advanced oxidation protein products. The data collected indicated that some OS outcomes were affected by the vitamin D supplementation, while others were not. This may be owing to the heterogeneity of study protocols regarding dose, length and the manner in which vitamin D was administered as well as to the heterogeneity of OS markers considered \[[@cit0006], [@cit0007]\].

Additionally, none of the studies focused on determining the effect of vitamin D on enzymes involved in both inflammation and ROS production, such as myeloperoxidase (MPO), or ROS generation, such as xanthine oxidase (XO), in patients with T2DM.

MPO is a multifunctional heme enzyme, serving as a typical immune defense enzyme against invading pathogens. It is localized in intracellular granules of neutrophils, monocytes and macrophages. As a marker of inflammatory response, it accounts for up to 5% of the total dry mass of mentioned inflammatory cells. It is responsible for the generation of bactericidal hypochlorous acid (HOCl), which has a strong oxidative property during respiratory burst reactions although it is not a free radical from the chemical point of view \[[@cit0008], [@cit0009]\].

Chronic activation of MPO may lead to oxidative modification of a number of cellular and extracellular biomolecules, such as cell signaling proteins, cysteine-rich peptides, extracellular matrix proteins, lipoproteins, cholesterol, membrane phospholipids and nucleic acids, with consequent production of haloamines, chloramines and bromamines. Oxidative modification of intracellular and membrane components of vascular endothelial cells may lead to the development of endothelial dysfunction, vascular damage and atherosclerosis. A causal relationship was documented by the accumulation of MPO in atherosclerotic lesions \[[@cit0010]--[@cit0015]\].

Besides the oxidative burst generated by the immune and inflammatory cell defense system, the other source of vascular superoxide in the circulation is the XO catalytic reaction. Being a part of the dehydrogenase-oxidase inter-convertible system, this molybdenum iron-sulfur enzyme exhibits broad substrate specificity, but the main substrates are the purine bases hypoxanthine and xanthine. The final oxidation product is uric acid (2,6,8-trioxypurine), accompanied by the release of superoxide anion radical (O~2~^--^) and hydrogen peroxide (H~2~O~2~) \[[@cit0016], [@cit0017]\].

In vascular endothelial cells, the enzyme may exist as cytoplasmic and membrane-bound XO. Capillary endothelial damage may liberate cytoplasmic enzyme, while the adhered immune cells may induce the release of membrane-bound XO. The oxidation of the sulfhydryl residues or limited proteolytic digestion may further contribute to production of XO on account of pre-existing xanthine dehydrogenase in ischemic conditions \[[@cit0018], [@cit0019]\].

A bidirectional relation between the two pro-oxidative enzymes XO and MPO is initiated on the one hand by XO-catalyzed liberation of ROS, which induce the release of pro-inflammatory cytokines, and activate neutrophils and macrophage cells, which consequently release MPO. On the other hand, MPO can use the XO-liberated product urate as a physiological substrate, producing urate radical, 5-hydroxyisourate and allantoin, which may exacerbate inflammatory tissue damage \[[@cit0020], [@cit0021]\].

The increased activity of both MPO and XO has been reported as a mediating risk factor for T2DM. The ROS produced by MPO and XO have been documented to be related to diabetic complications, especially to vascular remodeling, endothelial dysfunction, atherosclerosis and chronic diabetic vascular complications \[[@cit0022]--[@cit0024]\].

A chronic increase of ROS, presumably of H~2~O~2~, may induce oxidative damage of pancreatic β-cells, which in T2DM may further aggravate glucose homeostasis and metabolic control due to compromised insulin secretion. The first antioxidative defense enzyme capable of degrading H~2~O~2~ into oxygen and water is catalase. Clinical and experimental studies have confirmed a contributing role of reduced catalase activity in the development of T2DM, metabolic syndrome and insufficient pancreatic insulin secretion \[[@cit0025]--[@cit0028]\].

Taking into account the role of ROS and inflammation as interconnected players in atherosclerotic vascular complications of T2DM, we performed a study to test a possible anti-inflammatory and antioxidative effect of vitamin D supplementation through the activity of enzymes involved in ROS production (MPO and XO) and degradation (catalase) in patients with T2DM on therapy with metformin.

Material and methods {#sec2}
====================

Design and participants {#sec2.1}
-----------------------

The study is a 6-month follow-up, randomized, controlled open-label investigation into the effects of vitamin D supplementation on glycemic control and OS markers. A total of 140 patients with T2DM were recruited from the Primary Health Care Center in Podgorica, Montenegro in a summer-winter period. The eligibility criteria stipulated men and women ≥ 30 years old, who had good metabolic control (HbA~1c~ ≤ 7%) and who were being treated with metformin and offered lifestyle advice only. The study excluded patients who used diabetes pharmacotherapy other than metformin, vitamin D supplements, drugs which affect vitamin D metabolism (corticosteroids and anticonvulsants) or if they had severe anemia, chronic liver or kidney failure, alcohol addiction, pregnancy; malabsorption; urolithiasis; hypercalcemia; body mass index (BMI) ≥ 40 kg/m^2^ and any acute or chronic inflammatory condition. The study was conducted according to the Declaration of Helsinki and Good clinical Practice guidelines. The study protocol was approved by the Ethical Committee of Primary Health Care Center in Podgorica and written informed consent was obtained from all participants.

Intervention {#sec2.2}
------------

The participants were randomized to two groups (70 each) in the ratio 1 : 1. According to the US Endocrine society guidelines, the participants were considered vitamin D deficient if their 25(OH)D baseline levels were ≤ 50 nmol/l. Suspected vitamin D insufficiency was present if baseline levels were suboptimal, i.e. ≤ 75 nmol/l \[[@cit0029]\]. The participants from the first group (Intervention group) were prescribed one of two dosing regimens with cholecalciferol (vitamin D~3~), depending on the baseline vitamin D levels. If they were vitamin D deficient, along with metformin they received 50 000 IU of vitamin D~3~ weekly (divided into equal daily doses) for 3 consecutive months to correct deficiency, followed by 2000 IU daily (14 000 IU weekly) for the next 3 months to maintain sufficient vitamin D levels. The participants from the same group whose vitamin D baseline levels were ≥ 50 nmol/l received 2000 IU of vitamin D~3~ daily (14 000 IU weekly) along with metformin until the end of the study. Seventy participants from the second group (Metformin group) continued to receive only metformin During the 6-month study period.

The supplement adherence was carefully monitored. Twenty patients were excluded from the Intervention group since they did not adhere to the study protocol. In the Metformin group 2 patients were lost to follow-up ([Figure 1](#f0001){ref-type="fig"}).

![Participant flowchart and study design](AMS-16-5-39811-g001){#f0001}

Follow-up and outcome measurement {#sec2.3}
---------------------------------

Anthropometric and laboratory assessments were performed at baseline (prior to dosing) and 3 and 6 months after the study. Waist circumference, body height, weight as well as systolic (SBP) and diastolic (DBP) blood pressure measurements were described in detail elsewhere \[[@cit0030]\].

Body mass index was calculated as weight (kilograms) divided by height (meters) squared.

Venous blood samples were collected after an overnight fast between 7:00 and 9:00 a.m. Serum levels of fasting blood glucose (FBG), ionized calcium (Ca^++^), total cholesterol (TC), LDL cholesterol, HDL cholesterol and triglycerides (TG) were measured using standard enzymatic procedures (Roche Cobas 6000 c 501, Mannheim, Germany). The levels of HbA~1c~ were determined immunoturbidimetrically (Roche Cobas 6000 c 501, Mannheim, Germany) using full blood with K2EDTA anticoagulants. Fasting insulin (FI) and 25(OH)D serum levels were measured by commercial Roche tests based on the principle of electrochemiluminescence on the Cobas 6000/e601 automated analyzer (Roche Diagnostics, Mannheim, Germany).

Serum MPO activity was determined by a commercial ELISA test, using a pre-coated 96-well microplates with biotinylated target-specific antibodies. The sandwich assay is based on the reaction with the second (detector) antibody, when a substrate solution is added which reacted with the enzyme-antibody-target complex to produce coloring. The enzyme concentration was expressed as ng/l.

Serum XO activity was determined spectrophotometrically, based on the release of uric acid from xanthine as substrate \[[@cit0031]\], measured at 293 nm, with slight modification in serum assay conditions \[[@cit0032]\]. The enzyme activity was expressed as U/l.

Serum catalase activity was determined by using a spectrophotometric method, whereby the substrate hydrogen peroxide forms a stable yellow stained complex with molybdenum salts. The decrease in absorbance reflected the enzyme activity, expressed as Cat/l \[[@cit0033]\].

The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as formula: HOMA-IR = FBG (mmol/l) × FI (μIU/l)/22.5 \[[@cit0034]\].

The triglyceride-glucose (TyG) index was calculated as the natural logarithm (ln) of the product of FBG and TG using the formula: ln (TG \[mg/dl\] × fasting glucose \[mg/dl\]/2) \[[@cit0035]\].

Statistical analysis {#sec2.4}
--------------------

The data are expressed as means ± standard deviation (SD). For the comparison of the continuous variables between the groups Student's *t* test was used if the distribution was normal. The Mann-Whitney test was used as a nonparametric test for data not normally distributed. Skewed continuous variables were natural log transformed before the analysis. The changes in the parameters by group were monitored over time using repeated ANOVA measures. Mean differences between the groups after 3 and after 6 months were assessed using linear regression analysis. All effects were adjusted for gender, baseline age and BMI. The significant *p*-value was set as 0.05 (two-sided).

Statistical procedures were performed using R software (version 3.4.3) (R Foundation for Statistical Computing, Vienna, Austria) \[[@cit0036]\].

Sample size was calculated using the commercial statistical program G\* power for two-sided null hypothesis testing. The *F*-test or ANOVA for repeated measurements was used to determine the sample size in this software package. The estimated sample size was 49 patients per group considering type 1 error, α = 0.05 and statistical power 1 -- β = 0.8.

Results {#sec3}
=======

Out of 140 participants, 118 successfully completed the study and reported no adverse effects as the result of the intervention. The baseline characteristics of the study population did not differ significantly between the groups. In the Intervention group the mean age of the patients was 60.0 ±8.0 years and 55.9% were male. In the Metformin group the mean age was 64.4 ±8.1 years and 42.0% were male.

About half of the participants in the Intervention and Metformin group had deficient baseline vitamin D levels (50% vs. 36.8%). Suboptimal vitamin D status \[25(OH)D ≤ 75 nmol/l\] was observed in 84% participants in the Intervention group and in 76.4% in the Metformin group.

After 6 months of supplementation, vitamin D levels increased significantly in the Intervention group regarding baseline levels (*p* = 0.017). In the Metformin group vitamin D levels decreased significantly after 6 months (*p* \< 0.001).

Change in HbA~1c~ levels was also significant within both groups. In the Intervention group there was a significant decrease in HbA~1c~ levels in the 3^rd^ month of supplementation (*p* = 0.023), and then a significant increase in the 6^th^ month compared to the 3^rd^ month (*p* = 0.005). In the Metformin group a similar pattern of change in HbA~1c~ levels was observed but a significant difference was seen only between the 3^rd^ and 6^th^ month (*p* \< 0.001).

HOMA-IR did not change significantly within the groups (Intervention group *p* = 0.458, Metformin group *p* = 0.935).

A significant difference, to the detriment of the Metformin group, over the 3- and 6-month follow-up period was observed in the: vitamin D levels (39.45, *p* \< 0.001; 36.22, *p* \< 0.001), BMI levels (2.83, *p* = 0.045; 6.61, *p* = 0.005) and TyG index (--0.33, *p* = 0.003; --0.27, *p* = 0.028) when adjusted for gender, baseline age and BMI ([Table I](#t0001){ref-type="table"}).

###### 

Comparison of measured parameters over the 6-month follow-up period of vitamin D treatment

                         Intervention group   Metformin group   3 months        6 months                                                                                                         
  ---------------------- -------------------- ----------------- --------------- --------------- --------------- --------------- -------------------------- ---------- -------------------------- ----------
  Vitamin D \[nmol/l\]   52.98 ±22.20         112.54 ±23.63     92.00 ±20.29    64.40 ±25.52    74.29 ±22.46    56.80 ±19.82    39.45 (30.53--48.37)       \< 0.001   36.22 (28.42--44.02)       \< 0.001
  HbA~1c~ (%)            6.64 ±1.02           6.42 ±0.76        6.68 ±0.89      6.68 ±0.86      6.61 ±0.82      6.86 ±0.93      --0.16 (--0.46--0.14)      0.301      --0.14 (--0.50--0.22)      0.433
  FI \[μU/l\]            13.50 ±13.79         12.46 ±6.83       11.62 ±5.53     12.13 ±7.02     12.39 ±11.69    11.82 ±6.45     --0.36 (--3.98--3.27)      0.845      --0.33 (--2.63--1.96)      0.775
  BMI \[kg/m^2^\]        29.34 ±6.14          29.96 ±4.47       28.22 ±8.38     29.80 ±5.09     27.24 ±9.22     21.81 ±14.14    2.83 (0.06--5.60)          0.045      6.61 (2.06--11.16)         0.005
  WC \[cm\]              102.18 ±11.91        102.41 ±10.63     102.00 ±10.44   105.55 ±12.49   106.12 ±11.91   106.26 ±11.91   --2.59 (--5.67--0.49)      0.098      --2.59 (--6.12--0.93)      0.147
  HOMA IR                4.76 ±4.47           4.14 ±2.46        3.83 ±2.01      4.34 ±2.70      4.41 ±4.96      4.24 ±3.17      --0.33 (--1.86--1.19)      0.665      --0.32 (--1.28--0.65)      0.518
  FG \[mmol/l\]          7.93 ±2.37           7.40 ±1.18        7.34 ±1.34      7.92 ±1.43      7.96 ±1.74      7.74 ±1.49      --0.54 (--1.12--0.04)      0.066      --0.37 (--0.96--0.22)      0.216
  SBP \[mm Hg\]          136.85 ±23.35        142.38 ±16.94     137.28 ±17.90   139.05 ±19.12   142.11 ±17.30   141.05 ±16.62   1.77 (--5.30--8.84)        0.621      --3.52 (--10.58--3.53)     0.324
  DBP \[mm Hg\]          83.57 ±11.96         85.58 ±9.19       83.34 ±9.24     81.29 ±10.04    83.94 ±9.80     84.16 ±9.55     2.63 (--1.03--6.29)        0.157      --0.14 (--3.90--3.63)      0.943
  TG \[mmol/l\]          1.99 ±1.51           1.72 ±0.97        1.78 ±.98       1.95 ±0.95      2.16 ±1.06      2.30 ±2.06      --0.43 (--0.83-- --0.04)   0.032      --0.51 (--1.17--0.15)      0.130
  TYG                    9.21 ±0.76           9.07 ±0.61        9.10 ±0.60      9.31 ±0.52      9.40 ±0.51      9.36 ±0.61      --0.33 (--0.55-- --0.11)   0.003      --0.27 (--0.51-- --0.03)   0.028
  TC \[mmol/l\]          5.65 ±1.39           5.24 ±1.17        5.52 ±1.17      5.48 ±1.10      5.24 ±0.98      5.45 ±1.24      --0.12 (--0.56--0.31)      0.577      0.09 (--0.38--0.55)        0.713
  HDL \[mmol/l\]         1.37 ±0.34           1.34 ±0.32        1.38 ±0.30      1.27 ±0.30      1.20 ±0.26      1.26 ±0.33      --0.28 (--1.09--0.52)      0.485      0.10 (--0.02--0.23)        0.093
  LDL \[mmol/l\]         3.31 ±1.08           3.14 ±0.99        3.35 ±1.05      3.37 ±1.04      3.08 ±0.91      3.19 ±1.18      --0.52 (--1.49--0.45)      0.290      0.17 (--0.28--0.62)        0.462
  Ca^++^ \[mmol/l\]      2.45 ±0.16           2.44 ±0.16        2.48 ±0.14      2.41 ±0.10      2.40 ±0.10      2.44 ±0.10      0.01 (--0.02--0.04)        0.555      0.01 (--0.05--0.07)        0.817
  MPO \[ng/l\]           128.54 ±84.89        121.51 ±62.10     78.28 ±24.47    120.40 ±69.02   113.78 ±68.44   109.19 ±48.56   18.62 (--10.01--47.24)     0.200      --33.40 (--52.73--14.08)   0.001
  XO \[U/l\]             28.00 ±9.77          29.19 ±16.16      17.73 ±7.61     30.51 ±8.70     26.25 ±15.92    17.65 ±8.67     0.74 (--5.51--6.98)        0.815      --1.23 (--4.84--2.39)      0.501
  Catalase \[Cat/l\]     0.87 ±0.16           0.78 ±0.14        0.82 ±0.07      0.82 ±0.32      0.83 ±0.15      0.84 ±0.06      --0.01 (--0.07--0.05)      0.715      --0.20(--0.05--0.01)       0.127

Data are presented as mean ± SD. Adjusted for baseline age, BMI and gender.

Serum MPO was significantly reduced in the Intervention group over the period of study (*p* = 0.003). After 6 months, the MPO activity was significantly lower and gradually decreased, compared to the 3^rd^ month (*p* = 0.004) and about 40% compared to the baseline measurement (*p* = 0.015). In the Metformin group the MPO activity did not change significantly over time (*p* = 0.671) ([Figure 2](#f0002){ref-type="fig"}).

![MPO activity during the study (*p*-value on the graph -- from repeated measure analysis) (\**p* = 0.200 for Intervention vs. Metformin group after 3 months: *p* = 0.001 Intervention vs. Metformin group after 6 months)](AMS-16-5-39811-g002){#f0002}

After 6 months, the XO activity decreased significantly in the Intervention group compared to the baseline and 3^rd^ month levels (*p* \< 0.001) by more than 36%. The same pattern was observed in the Metformin group, with a significant change between baseline and the 6^th^ month (*p* \< 0.001) and between the 3^rd^ and 6^th^ month (*p* = 0.003) ([Figure 3](#f0003){ref-type="fig"}).

![XO activity during the study (*p*-value on the graph -- from repeated measure analysis) (\**p* = 0.815 for Intervention vs. Metformin group after 3 months: *p* = 0.501 Intervention vs. Metformin group after 6 months)](AMS-16-5-39811-g003){#f0003}

The catalase activity significantly decreased in the Intervention group after 3 months (*p* = 0.010), but after 6 months of supplementation there was a significant increase compared to the 3^rd^ month (*p* = 0.027).

In the Metformin group the initial and final catalase activity did not differ significantly (*p* = 0.809).

At the end of the study a significant difference between the groups regarding OS biomarkers was seen only in MPO levels (*p* = 0.001) ([Table I](#t0001){ref-type="table"}).

Discussion {#sec4}
==========

Our study showed that vitamin D supplementation in patients with T2DM resulted in a significant decrease in pro-inflammatory and pro-oxidant enzymes MPO and XO as well as a significant increase in antioxidative enzyme activity (as measured with catalase activity). To our knowledge, none of the previous researchers investigated the effects of vitamin D on both enzymes (XO and MPO) in patients with T2DM.

Our study showed a significant decrease of MPO within the Intervention group, but also a significant mean difference between the groups after 6 months (*p* = 0.001). Only one study evaluated the effect of vitamin D on MPO activity in T2DM patients \[[@cit0037]\]. Our results are partially in accordance with the study conducted by Nikooyeh *et al.*, which demonstrated that the consumption of vitamin D fortified yogurt decreased MPO activity within the vitamin D group, but failed to demonstrate a significant difference when compared to the group which consumed plain yogurt \[[@cit0037]\]. This may be due to the consumption of lower vitamin D doses (500 IU daily) compared to the doses in our study (7120 IU daily and/or 2000 IU daily).

It is well documented that MPO is a multifunctional enzyme, which may generate different ROS. The reaction is initiated by the assembly of one NADPH oxidase with plasma membrane, followed by the release of O~2~ ^•--^, which may dismutate to H~2~O~2~. Finally, reactive HOCl is generated in the presence of H~2~O~2~ and the chloride ion. Generated HOCl, judging by the oxidative properties, helps in destroying microbes and malignant cells \[[@cit0008], [@cit0038]\].

A number of the cell and extracellular biomolecules containing nitrogen can be a target for HOCl attack, when multiple types of chloramines are formed, presumably in reactions with histidine, lysine and arginine, purine and pyrimidine bases, nucleosides, nucleotides, DNA, RNA, amino sugars and glycosaminoglycans and amino alcohols of phospholipids \[[@cit0010], [@cit0039]\]. Susceptible amino acids in proteins are tyrosine and cysteine. MPO-induced oxidative modification of tyrosine generates halotyrosines, 3-chlorotyrosine, 3,5-dihalotyrosine and dityrosine \[[@cit0012], [@cit0040]\].

MPO is a pro-oxidant enzyme, also involved in pathogenesis of atherosclerosis as it modifies lipoprotein particles, particularly atherogenic LDL lipoprotein. In this way, both the apoprotein structure and lipid core of LDL cholesterol are subject to oxidative modification to a more atherogenic form, which can avoid LDL-receptor stimulated and controlled uptake and favor scavenger receptor LDL uncontrolled uptake followed by the formation of foam cells. The target chemical composition of oxidative damage is a double bond in the structure of unsaturated fatty acids and cholesterol in circulating lipoproteins and structural phospholipids and cholesterol localized on the cell membrane. In this way substrates, the unsaturated fatty acids and cholesterol form chlorohydrins and N,N-dichlorinated phospholipids, after exposure to HOCl. The oxidative modification of HDL cholesterol forms a dysfunctional oxidized form \[[@cit0014], [@cit0015], [@cit0041]--[@cit0044]\]. Oxidatively modified tyrosine derivatives, together with MPO and activated macrophages, have been found in atherosclerotic lesions. Oxidatively modified cysteine may generate a cross-link with lysine or arginine, with the formation of sulfenic or sulfinic acid intermediates. Stimulated production of collagen by MPO may also contribute to vascular and extracellular matrix remodeling \[[@cit0013], [@cit0045]--[@cit0048]\].

The results obtained may be of importance in preventing the development and progression of cardiovascular diseases, by protecting coronary arteries from atherosclerotic and endothelial damage \[[@cit0049]\].

XO is an enzyme which plays an important role in purine catabolism by catalyzing the terminal oxidation of hypoxanthine to xanthine to uric acid \[[@cit0050]\]. A reaction catalyzed by XO produces free radicals, the superoxide anion radical and hydrogen peroxide. Along with uric acid, they have been implicated in several damaging pathways resulting in endothelial dysfunction in T2DM patients \[[@cit0051], [@cit0052]\]. Although the literature regarding XO and T2DM association in humans is obscure, it has been proposed that the inhibition of XO activity leads to improved endothelial function in patients with T2DM and associated mild hypertension \[[@cit0053]\].

The results from our report showed a significant decrease in XO activity in the Intervention group after 6 months of supplementation with vitamin D. In the Metformin group there was also a significant decrease in XO activity after 6 months. A plausible explanation for the lack of significant mean difference between groups could be that our patients had good metabolic control, while hyperglycemia is one of the stimuli that trigger XO release from damage after inflammatory attack on vascular endothelial cells in T2DM patients \[[@cit0023], [@cit0054]\]. Other stimuli include hypoxia and hypercholesterolemia \[[@cit0050], [@cit0055]\]. Besides metabolic control, studies also reported some other confounders which can influence XO activity. Metformin could be one of them. Ćosić *et al.* found that metformin produced a significant reduction of XO activity, which was greater than the relatively small decrease in the concentration of glucose \[[@cit0056]\].

The antioxidant status in our patients was evaluated through catalase activity. This hemoprotein is the main regulator of H~2~O~2~ degradation \[[@cit0025]\]. It scavenges excessive H~2~O~2~ produced by XO and other prooxidants, preventing ROS-mediated cell damage in that way. Many studies have demonstrated diminished antioxidative defense in patients with T2DM \[[@cit0057]\]. According to the literature, vitamin D could enhance ROS removal by stimulating the activity of antioxidative enzymes. One of the proposed mechanisms is that vitamin D regulates expression of genes involved in the control of several antioxidative and detoxifying enzymes \[[@cit0058], [@cit0059]\]. In accordance with our expectations, study data showed a significant increase in catalase activity after long-term supplementation in the Intervention group while there was no significant change in the Metformin group. Alatawi *et al.* also demonstrated that vitamin D and Ca supplementation resulted in a significant increase in catalase activity in streptozotocin-induced diabetic rats \[[@cit0060]\].

Vitamin D effects related to the ROS-inflammation axis have been proposed recently and have not been well studied so far. The data from experimental studies implied that vitamin D supplementation could have beneficial effects mainly through decreasing lipid peroxidation and improving antioxidative defense \[[@cit0061]\].

In conclusion, our study sheds light on a novel mechanism of both anti-inflammatory and antioxidative effects of vitamin D through the influence on MPO, XO and catalase activity. In this way, vitamin D could improve endothelial dysfunction in patients with T2DM on metformin therapy by influencing two important factors implicated in pathogenesis of diabetic complications -- ROS production and inflammation, which can additionally contribute to stable metabolic control.
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